Company Overview and News

0
An evening walk down Dalal Street | Sensex up almost 200 pts, Nifty back at 11,000

9h moneycontrol
After starting the week on a negative note, the market on Tuesday looked to reclaim its positive momentum from last week, backed by sharp gains in midcaps. The Sensex managed to end the day almost 200 points higher, while the Nifty managed to end above 11,000-mark.
IOC 500469 532617 TCHQY HINDUNILVR FEDA 532755 532187 532461 FEDS 500696 500477 FEDERALBNK ASHOKLEY SBAZ INDIGO INDUSINDBK JETAIRWAYS FDBAY 530965 AKLD TECHM 539448 PNJZY PNB AKLS

0
Tech Mahindra Limited - Allotment of ESOP/ESPS

2018-07-13 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
TCHQY 532755 TECHM

9
Accenture’s growth forecast puts spotlight on Indian rivals

2018-07-10 livemint
Bengaluru: Accenture Plc will add more than $4.37 billion in incremental revenue in the fiscal year ending August 2018, the highest new revenue done by an information technology (IT) outsourcing company in over two decades.
HCTHY INFY TCHQY TTNQY 532755 CTSH TECHM WIT 532540 HCLTECH ACN 532281 TCS

0
Tech Mahindra Limited - Updates

2018-07-09 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
TCHQY 532755 TECHM

3
Tech Mahindra CEO C.P. Gurnani’s salary was ₹ 146.19 crore in FY18

2018-07-09 livemint
Bengaluru: Tech Mahindra’s chief executive officer C.P. Gurnani earned ₹ 146.19 crore in remuneration in 2017-18, bringing his total earnings over the last five years to ₹510 crore. The numbers have rekindled debate among analysts and observers on compensation for the CEO of India’s fifth largest software services company and how it compares with the median salary of its other employees.
WIT 532540 HCLTECH HCTHY INFY 532281 TCHQY TCS TTNQY 532755 TECHM

1
TCS hits fresh record high; brokerages betting on strong Q1 earnings growth

2018-07-06 moneycontrol
Tata Consultancy Services created history on Friday as it touched a fresh record high above Rs 1,900 per share, supported by expectations of strong growth in the June quarter and depreciation in the rupee against the dollar.
500325 RELIANCE HCTHY TCHQY TTNQY 532755 TECHM 532540 HDB 500180 RIGD HCLTECH 532281 HDFCBANK TCS RLNIY

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

15h - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

17h - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CUSIP: 00B1C4TB0